Spałek Mateusz Jacek, Czarnecka Anna Małgorzata, Rutkowski Piotr
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland.
J Clin Med. 2021 Feb 10;10(4):694. doi: 10.3390/jcm10040694.
(1) Background: Radiation-induced sarcomas (RIS) are rare diseases with poor prognoses. The aim of the study was to analyze outcomes and identify factors affecting survival in a cohort of patients with RIS. (2) Methods: We included consecutive patients with RIS that we found in the available electronic medical records of a sarcoma tertiary center. We analyzed patients' RIS characteristics, management of RIS, the occurrence of local recurrence and distant metastases, the date of disease progression, the date of death, and the date of the last follow-up. (3) Results: Fifty-eight patients met the inclusion criteria. The most frequent sites of RIS development were the thorax and pelvis. The majority of RIS were poorly differentiated, high-grade tumors. Forty patients underwent surgery or radiotherapy with curative intent. The others were referred to palliative chemotherapy. Median progression-free survival and overall survival were 15 and 21 months, respectively. Treatment with curative intent and tumor localization on breasts and upper extremities were associated with a lower risk of death in univariate analysis. (4) Conclusions: The study confirms the poor prognosis of RIS. Treatments with locally curative intent at the tumor site are of prognostic value. Secondary radiotherapy is rarely used in RIS.
(1) 背景：放射性肉瘤（RIS）是一种罕见疾病，预后较差。本研究的目的是分析一组RIS患者的治疗结果，并确定影响生存的因素。(2) 方法：我们纳入了在一家肉瘤三级中心的可用电子病历中发现的连续的RIS患者。我们分析了患者的RIS特征、RIS的治疗、局部复发和远处转移的发生情况、疾病进展日期、死亡日期以及最后一次随访日期。(3) 结果：58例患者符合纳入标准。RIS最常见的发生部位是胸部和骨盆。大多数RIS是低分化的高级别肿瘤。40例患者接受了根治性手术或放疗。其余患者接受姑息化疗。无进展生存期和总生存期的中位数分别为15个月和21个月。在单因素分析中，根治性治疗以及肿瘤位于乳房和上肢与较低的死亡风险相关。(4) 结论：本研究证实了RIS预后较差。在肿瘤部位进行局部根治性治疗具有预后价值。二次放疗在RIS中很少使用。
